Medicine & Pharmaceuticals News
Alfa Cytology Integrates BNCT Drug Development and Preclinical Validation Capabilities to Accelerate Translational Research
With the continuous development of precision cancer therapy, Boron Neutron Capture Therapy (BNCT) is becoming an important direction of targeted cancer therapy. To meet the growing demand for BNCT research, Alfa Cytology has expanded its integrated BNCT drug development services together with a specialized preclinical evaluation system to support drug candidate screening, boron carrier optimization, and translational oncology research. The drug development of BNCT involves multiple complex steps, such as boron compound screening, vector design, functional verification, and preclinical evaluation. Relying on the BNCT development services framework, Alfa Cytology integrates research and development resources to help research teams establish a systematic research pipeline from candidate discovery to in vivo validation. By connecting early-stage drug development and preclinical research through an integrated research workflow, the company aims to reduce technical barriers to BNCT drug development and improve the efficiency of translational research. Within this integrated research framework, Alfa Cytology supports boron carrier development and candidate optimization studies. The framework integrates advanced drug design and research strategies to assist researchers in developing boron delivery systems that can selectively enrich tumors based on the characteristics of the tumor microenvironment. At the same time, Alfa Cytology also supports multimodal treatment studies and experimental verification of boron distribution related to biological behavior. Through biodistribution analysis using PET and SPECT imaging , researchers can further evaluate the in vivo distribution characteristics of boron-containing candidates, providing a key database for subsequent preclinical studies. Based on functional validation studies, Alfa Cytology has further established a professional preclinical evaluation system to analyze the targeting ability, therapeutic potential, and biological safety of BNCT candidates. By constructing orthotopic, metastatic, PDX, and drug-resistant tumor models, the laboratory can carry out tumor growth monitoring, tumor microenvironment analysis, and in vivo distribution study. These experiments not only provide key data support for optimizing treatment strategies but also help to improve the efficiency of translational oncology research. In addition, the integrated research system also supports the study of combination therapy strategies and covers candidate screening, functional analysis, and in vivo validation. Allowing research teams to complete multiple key validation phases within the same research workflow helps improve study continuity and accelerate the development of innovative BNCT treatment strategies. "Preclinical validation data are essential to assess the feasibility of BNCT treatment strategies," said a spokesperson for Alfa Cytology. "By integrating BNCT drug development services with specialized preclinical evaluation capabilities, we are committed to supporting innovative oncology research and helping research teams more efficiently advance translational research." About Alfa Cytology Alfa Cytology focuses on preclinical research support for cancer therapy development and innovative oncology strategies. They provide systematic research solutions to biotechnology companies, pharmaceutical institutions, and research organizations around the world. By integrating advanced experimental techniques, tumor model resources, and professional research platforms, Alfa Cytology provides experimental systems and technical support for a variety of translational oncology research, helping to accelerate the progress of research results from the laboratory to the preclinical stage.
Alfa Cytology Aligns Bacterial Engineering with In Vivo Validation to Enable Rapid Oncolytic Drug Development
Ace Therapeutics Expands Comprehensive Heart Disease Research and Drug Development Solutions
Amerigo Scientific Rolls Out Comprehensive Portfolio of High-Performance Chiral Columns for Multi-Industry Enantiomer Separation
- May 28, 2026Medicine & Pharmaceuticals
Alfa Chemistry Advances Biomedical Research with High-Performance Polymer Microspheres
Alfa Chemistry announced the expansion of its advanced polymer microspheres portfolio through its Colloidal Materials Division to support biomedical research involving drug delivery, regenerative medicine, tissue engineering, diagnostics, and functional biomaterials development. Polymer microspheres are increasingly utilized in biomedical systems because their particle morphology, degradation behavior, surface chemistry, and encapsulation performance can be engineered for specific therapeutic and analytical requirements. In controlled-release formulations, microsphere-based carriers can reduce burst release, improve localized retention, and prolong therapeutic exposure of bioactive compounds including peptides, biologics, hydrophobic drugs, and growth factors. Among biodegradable carrier systems, poly(L-lactic acid) (PLLA) microspheres are widely studied for scaffold engineering and sustained-release applications due to their favorable balance between mechanical stability and hydrolytic degradability. Compared with several fast-degrading polyester systems, PLLA exhibits slower degradation kinetics, enabling prolonged structural support and extended release behavior in biomedical formulations. PLLA microspheres are frequently incorporated into porous scaffold systems designed to support cell adhesion, extracellular matrix formation, and tissue regeneration. Their degradation profile also enables temporal control of therapeutic release in long-term delivery systems investigated for peptides, anti-inflammatory compounds, and regenerative therapeutics. Another important biodegradable delivery platform is polycaprolactone (PCL) microspheres , which are recognized for their semicrystalline structure, high drug permeability, and exceptionally slow hydrolysis rate. Due to their prolonged degradation behavior, PCL-based microspheres are increasingly evaluated for long-acting injectable formulations, implantable delivery systems, and regenerative medicine applications requiring extended therapeutic release. PCL microspheres are also being investigated in hybrid biomaterial systems where scaffold stability and controlled growth factor release are required over extended periods. Their slower degradation kinetics can help maintain construct integrity during long-term regenerative processes. In addition to biodegradable biomaterials, non-biodegradable microspheres remain important in analytical and diagnostic technologies. Poly(methyl methacrylate) (PMMA) microspheres are valued for their optical transparency, chemical stability, mechanical robustness, and controlled particle uniformity. These characteristics support applications involving immunodiagnostics, calibration standards, bioseparation systems, imaging technologies, and microfluidic analytical platforms. PMMA microspheres are also utilized as functional substrates for ligand immobilization and surface engineering in biosensing workflows due to their tunable surface chemistry. “Material reproducibility, degradation control, and particle uniformity are becoming increasingly important in advanced biomedical systems,” said a technical representative from Alfa Chemistry. “Polymer microspheres with tunable physicochemical properties can support more precise therapeutic delivery, scaffold engineering, and analytical performance across a wide range of biomedical applications.” With nearly two decades of experience in colloidal materials development, Alfa Chemistry’s Colloidal Materials Division provides standard and customized microsphere solutions, as well as custom development and characterization services, for biomedical and advanced material research applications. About Alfa Chemistry Alfa Chemistry is a global CRO specializing in organic chemistry, material chemistry, medicinal chemistry, and advanced materials. Through its Colloidal Materials Division, the company develops and supplies innovative colloidal materials for applications in biomedicine, diagnostics, catalysis, energy systems, and functional materials research.
- May 27, 2026Medicine & Pharmaceuticals
Creative Biolabs Elevates Therapeutic Antibody Development via Enhanced Fc Silence Engineering Platforms
By integrating advanced rational mutagenesis, post-translational modification screening, and comprehensive functional validation, the company offers a highly connected and data-backed workflow for immune effector modulation. 、 At the heart of this enhancement is a seamless synergy between structural engineering and laboratory validation. Creative Biolabs' specialized Fc engineering service for Fc silence connects molecular design with rigorous experimental testing. While conventional monoclonal antibodies leverage effector functions to eradicate tumor cells, these mechanisms can trigger severe side effects in antagonist therapies. This approach supports more informed candidate prioritization by decoupling antigen-binding affinity from destructive immune system recruitment. "Our platform is designed to transition from automated molecular optimization to experimental confirmation more efficiently," said a senior scientist from Creative Biolabs' antibody engineering team. "The goal is to eliminate unwanted immune activation while maintaining crucial pharmacokinetic properties to refine the lead optimization process." Mitigating Risk Through Multi-Species Fc Silence Platforms To address high attrition rates in preclinical pipelines, Creative Biolabs has strengthened its proprietary Fc silence engineering service . Utilizing precise amino acid substitutions and aglycosylation strategies, the service aims to assist in predicting and eliminating interactions with activating Fcγ receptors (FcγRs) and serum complement components more effectively than traditional trial-and-error methods. By neutralizing potential liabilities—such as antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC)—early in the pipeline, the workflow enables the proactive design of molecules with improved safety profiles. This comprehensive platform supports modifications across human, mouse, and rabbit IgGs, ensuring that resources are focused on candidate molecules with the highest potential for successful translational development. Advanced Structural Modification for Extended Drug Half-Life To further support the optimization stages of the therapeutic cycle, Creative Biolabs offers specialized therapeutic Fc engineering technology . This service complements effector silencing by providing structural tuning for: Neonatal Fc receptor (FcRn) binding enhancement. Serum half-life prolongation and preclinical evidence generation. These molecular optimizations directly support subsequent disease model characterization, in vivo evaluation, and robust preclinical evidence generation. By optimizing pH-dependent FcRn interactions without altering the silenced effector domain, the platform assists researchers in maintaining the prolonged circulation profiles necessary for practical clinical dosing regimens. FAQ: Therapeutic Fc Engineering and Fc Silence How does the platform eliminate effector functions without altering antigen specificity? The platform introduces specific mutations into the heavy chain CH2 domain, disrupting the structural binding interfaces required for FcγR and C1q engagement while leaving the Fab variable regions entirely untouched. What are the primary deliverables of this service? Clients receive a ranked candidate list, optimized antibody sequences, detailed Fc-receptor binding affinity reports, and comprehensive in vitro functional validation results. Key Takeaways Integrated Workflow: Connects structural Fc design, aglycosylation strategies, and biological testing. Lead Optimization: Balances target blockade, safety profiles, and pharmacokinetics through rational engineering. Wet-Lab Validation: Confirms silenced candidates through in-house experimental reporter assays. Translational Insights: Multi-species platforms support cross-reactivity testing and disease model evaluation. About Creative Biolabs Creative Biolabs provides end-to-end support for the global biotechnology and pharmaceutical industries. From initial target identification to preclinical candidate selection, the company's multidisciplinary team combines biological expertise with antibody engineering technology to accelerate drug discovery pipelines.
- May 26, 2026Medicine & Pharmaceuticals
Creative Biolabs Advances Integrated Target and TME Workflows to Accelerate Pancreatic Cancer Immunotherapy Research
By integrating high-affinity antibodies targeting Epithelial-Mesenchymal Transition (EMT) pathways, immune checkpoints, and tumor microenvironment (TME) factors, the company offers a more connected and mechanism-backed workflow for pancreatic cancer research. Bridging the Gap Between Tumor Invasion and Immune Evasion At the heart of this enhancement is a seamless synergy between targeting cellular plasticity and evaluating immune responses. Creative Biolabs' synchronized research workflow connects the study of tumor invasion mechanisms with the analysis of immunosuppressive microenvironments. This approach supports more informed target validation by combining specialized antibody reagents with comprehensive validation assays. "Our platform is designed to transition from identifying metastatic drivers to assessing immune-exclusion mechanics more efficiently," said a senior scientist from Creative Biolabs' oncology research team. "The goal is to analyze the crosstalk between EMT and the surrounding stroma simultaneously to refine the lead discovery process in pancreatic ductal adenocarcinoma (PDAC)." Mitigating Resistance Through Multi-Target TME Profiling To address high attrition rates in pancreatic cancer immunotherapy, Creative Biolabs has strengthened its portfolio of immune checkpoint and tumor microenvironment antibodies . Utilizing highly validated clones, the service aims to assist in profiling myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and regulatory T cells more effectively than standard screening methods. By identifying critical immunosuppressive liabilities early in the pipeline, the workflow enables the proactive evaluation of therapeutic strategies, such as novel combination therapies or bispecific antibody designs. This characterization capability helps ensure that research resources are focused on mechanistic pathways with the highest potential for breaking tumor resistance. Targeted Portfolios for Tumor Plasticity and Maturation Stages To further support the exploration of tumor progression, Creative Biolabs offers specialized tools focused on EMT and tumor invasion antibody research . This selection complements microenvironment analysis by providing high-specificity antibodies for: Detection of key transcription factors (e.g., Snail, Slug, Twist) driving cellular plasticity. Quantification of matrix metalloproteinases involved in basement membrane degradation. Assessment of cell surface marker shifts during mesenchymal transition. By tracking morphological patterns and providing highly reproducible data, the comprehensive catalog assists researchers in interpreting complex biological responses within the pancreatic cancer research portal during translational oncology programs. FAQ: Pancreatic Cancer TME and EMT Antibody Workflows How do EMT and TME crosstalk impact pancreatic cancer resistance? EMT pathways do not only facilitate metastasis; they also actively drive the secretion of immunosuppressive cytokines that polarize surrounding immune cells, establishing a protective stromal shield around PDAC tumors. What validation data accompanies these antibody portfolios? Reagents undergo rigorous application-specific testing, including immunohistochemistry (IHC) on complex tissue matrices, flow cytometry, and Western blotting (WB) to ensure minimal background noise. Who can benefit from this integrated workflow? This workflow is tailored for biotech, pharma, and academic teams focused on pancreatic oncology, immunotherapy resistance, and translational stroma research who need to bridge the gap between target identification and wet-lab validation. Key Takeaways Integrated Workflow: Connects tumor plasticity analysis with microenvironment immune profiling. Resistance Mitigation: Helps target the immunosuppressive components of dense pancreatic tumor stroma. Validated Tools: Highly specific antibodies confirmed through rigorous application testing (IHC/WB/FC). Translational Insights: Supports multi-parameter evaluation to accelerate combination therapy discovery. About Creative Biolabs Creative Biolabs specializes in recombinant antibody development services for the biotechnology and pharmaceutical industries. The company supports clients with antibody discovery, engineering, humanization, and validation to accelerate therapeutic and diagnostic development.
- May 22, 2026Medicine & Pharmaceuticals
The 'Pharmacy Secret' Behind K-Beauty's 20x Growth is Finally Hitting Amazon
A South Korean skincare brand is making a calculated push into the North American market, using clinical research to carve out space on Amazon against a wave of competing beauty labels. Rawdive, a derma-focused brand that built its reputation through South Korean pharmacy channels, has been pouring resources into digital advertising and Amazon promotions as of May 2026, pitching North American shoppers on what it describes as a science-first approach to K-skincare. From Korean Drugstores to U.S. Doorsteps The brand's hero product, the Heartleaf Cica Calming Gel Cleanser, is built around a blend of plant-based and active ingredients. At its core is the "Heartleaf Cica 9X Soothing Complex," formulated with 100% pure heartleaf powder and centella asiatica extract — both widely recognized in dermatology for their skin-calming properties. BHA and succinic acid, the latter known as a powerful yet non-irritating active ingredient, penetrate deeper to clear oil and buildup, with clinical testing confirming a 99.8% impurity removal rate. The clinical data behind the formula is extensive. A trial on acne-prone participants showed that two weeks of use led to a 24.06% reduction in acne coverage, a 38.12% drop in papules, and a 72.22% decrease in pustules. Single-use testing recorded a 40.44% reduction in sebum and a 96.77% surface impurity removal rate. In a separate skin sensitivity assessment, the formula scored an irritation index of just 0.03 — earning a formal "non-irritating" designation. Triple ceramides and ten forms of hyaluronic acid round out the formula, supporting hydration and barrier repair through a coconut-derived, low-irritant surfactant system that maintains a low pH without compromising cleansing performance. That exceptionally low irritation profile makes the cleanser well suited for the whole family. Teenagers dealing with hormonal breakouts can benefit from its acne-targeting actives, while parents with more sensitive or mature skin can use it with confidence — a rare combination of efficacy and gentleness that spans generations. Repeat Purchase Rates Reflect Real-World Results Beyond the lab, Rawdive's sales trajectory is equally compelling. The brand recorded a 20-fold revenue increase within its first 18 months in South Korea — and perhaps more tellingly, a 40% repurchase rate among buyers in its acne and oily skin line. In a category where consumers move on quickly when results fall short, that level of retention speaks for itself. At home, Rawdive secured pharmacy shelf space in Seoul's Myeongdong and Seongsu neighborhoods, passing rigorous verification by demanding Korean consumers and pharmacists. This placement functions as South Korea's unofficial seal of approval for safety and efficacy, signaling credibility earned through rigorous retail channels that Rawdive is now bringing to North American consumers.
- May 22, 2026Medicine & Pharmaceuticals
Duopharma Biotech Contributes to National Pharmaceutical Self-Reliance Through Manufacturing Capacity and Portfolio Growth
Duopharma Biotech Contributes to National Pharmaceutical Self-Reliance Through Manufacturing Capacity and Portfolio Growth Business roadmap supports regional market ambitions and aligns with goals of New Industrial Master Plan 2030 and 13th Malaysia Plan Duopharma Biotech Berhad ("Duopharma Biotech" or "the Company") held its 25th Annual General Meeting today, capping a successful FY2025 ended 31 December 2025, that saw the Company growing its revenue by 14.5% to RM931.69 million, from RM813.70 million in FY2024. The sustained double-digit growth was primarily driven by resilient demand from both the public and private sectors across all business segments, complemented by a one-off surge in insulin supply. Profit Before Tax ("PBT") saw markedly strong growth, rising 43.6% year-on-year, and breaching RM100 million for the first time to hit RM114.91 million. In addition to higher revenue, the performance was mainly due to continued favourable API costs, positive foreign exchange movements and improved operational efficiency. Consequently, the Board of Directors announced a second interim dividend of 3.05 sen per share (FY2024: 2.0 sen), adding to the first interim dividend of 1.5 sen (FY2024: 1.0 sen) per share, bringing the total dividend for FY2025 to 4.55 sen (FY2024: 3.0 sen) per share). The total dividend payout of RM43.77 million (FY2024: RM28.86 million), comprising approximately 50% of the total Profit After Tax, was 51.7% higher year-on-year, demonstrating the Company’s commitment to attractive shareholder returns. Duopharma Biotech Chairman Datin Paduka Kartini Haji Abdul Manaf commented: “As a Malaysian pharmaceutical leader and Government-linked Corporation, Duopharma Biotech is proud to play our role in ensuring Malaysia’s healthcare ecosystem remains resilient amidst global uncertainties, supporting national priorities by ensuring reliable access to high quality, locally-manufactured medicines for everyone. We aim to provide smarter solutions for a healthier life, via a broader product portfolio, Halal offerings that meet consumer needs and enhanced manufacturing capacity. Guided by the pillars of our ESG Strategy including Sustainable Supply Chain and Access to Medicine, our offerings target to meet growing domestic needs, such as the many Malaysians living with diabetes, hypertension and high cholesterol highlighted in the recently published National Health and Morbidity Survey ("NHMS") 2025.” Duopharma Biotech Group Chief Executive Officer Wan Amir-Jeffery Wan Abdul Majid remarked, “2025 was a strong year of business performance where Duopharma Biotech continued to ensure a reliable supply of medicines in-country, as well as in our international markets. This was supported by having robust domestic manufacturing capacity in pharmaceuticals which is critical in safeguarding medicine supply in Malaysia. We can see the Government’s attention through major national policies such as the 13th Malaysia Plan ("RMK-13") that encourages domestic manufacturing and greater self-reliance in pharmaceutical supply chains, as well as the New Industrial Master Plan 2030 ("NIMP 2030") that earmarks the pharmaceutical sector as a Key Growth Segment, aiming to enhance the manufacturing of biologics, generics and active pharmaceutical ingredients ("API"), as well as the production of Halal medicines. At Duopharma Biotech, we will continue expanding our portfolio via new products developed in-house and partnerships with innovative technology players.” A Strategic and Comprehensive Portfolio In FY2025, the Company achieved a significant milestone by becoming the first company in the world to obtain Halal certification from JAKIM for its biologic product, namely an erythropoietin biosimilar used in the treatment of anaemia among chronic kidney disease patients. In FY2026, the Company will continue expanding its portfolio for treating non-communicable and chronic conditions. The focus on diversification continued in Consumer Healthcare, with the introduction of CHAMPS® Nutribar to offer Vitamin C added as a healthy snack for children, and FLAVETTES® MsRange powdered food supplement for beauty and wellness in women. In addition, the new PROVITON® STR offered energy gels for revitalisation and endurance in sports. Duopharma Biotech remains a key supplier to the Ministry of Health ("MOH"), currently supplying pharmaceutical and non-pharmaceutical products in the Approved Products Purchase List ("APPL") to Government-operated healthcare facilities until 31 December 2026. The company is also contracted to supply Insulin Aspart to MOH facilities from 6 February 2026 to 5 February 2028, valued at about RM53 million, and recently completed a three-month interim contract (with partner Biocon) to supply Recombinant Human Insulin to MOH facilities from 16 February to 15 May 2026, valued at approximately RM65 million. Changes in Leadership FY2025 witnessed key changes in Duopharma Biotech’s Senior Management and Board of Directors. Wan Amir-Jeffery Bin Wan Abdul Majid was appointed Group Chief Executive Officer, taking over from former Group Managing Director Leonard Ariff Bin Abdul Shatar, while Rohayu Rosnani Binti Mohd Adanan took over the Chief Financial Officer position from Chek Wu Kong. In addition, Noor Aida Binti Jaafar was promoted to Chief Commercial Officer. The Board of Directors welcomed four new Independent Directors: Datuk Wira Arham Bin Abdul Rahman (Senior Independent Non-Executive Director), Dato’ Adnan Hisham Bin Pawanteh, Dr Sharmila A/P Ramachandran and Dr Hasnita Binti Hashim, as well as Non-Independent Director Mohamad Idros Bin Mosin. They replaced outgoing Board members Razalee Bin Amin, Datuk Nik Moustpha Bin Haji Nik Hassan, Zaiton Binti Jamaluddin, Dato’ Dr Zaki Morad Bin Mohamad Zaher, Mohd Haris Bin Mohd Arshad and Dato’ Eisah Binti A. Rahman. Continued Recognition Across FY2025, Duopharma Biotech continued to garner accolades. Key wins include the Prime Minister’s Award (Private Sector) and the Gold Award (Private Sector) at the Integrity, Governance and Anti-Corruption Award ("AIGA") 2025 by the Malaysian Institute of Integrity. At the MSWG National Corporate Governance & Sustainability Awards ("NACGSA") 2025, the Group was ranked among the Top 20 companies for Overall Excellence and received the Mid Cap Excellence Award for companies with market capitalisation between RM1 billion and RM2 billion. The Company was also honoured with the Excellence Award (Silver) for companies with less than RM2 billion in market capitalisation at the National Annual Corporate Report Awards ("NACRA") 2025, and received international recognition with the Excellence in Governance (ESG) Award at the CSIA Global Governance Awards 2026 and the Technology & Innovation Excellence Award at the World Halal Excellence Award ("WHEA"). On the Human Resource front, Duopharma Biotech emerged Champion in the Graduates’ Choice of Employer (Pharmaceutical) category at the 8th Talentbank Graduates’ Choice Awards 2026, a heartening endorsement of trust among youths, after coming in second in the previous six years. Meanwhile, the Company’s established consumer brands continued to be recognised, with CHAMPS® Vitamin C named the Most Voted Kid’s Supplement in the Guardian Awards 2025’s Fan Favourites segment, while UPHAMOL® and FLAVETTES® respectively took Silver and Bronze in the Health category at the Putra Aria Brand Awards 2025.
- May 22, 2026Medicine & Pharmaceuticals
Rock Hill, SC Cosmetic Dentistry: Tooth Restoration & Whitening Services Updated
Rock Hill-based River District Smiles Dentistry has announced an update to its range of cosmetic dental services, now encompassing restorative treatments for cracked or chipped teeth, professional teeth whitening, porcelain veneers, and the latest denture and implant solutions. The expanded offering reflects growing patient demand for personalized cosmetic dental treatments in the region. More details can be found at https://riverdistrictsmiles.com/ Central to the updated service is a structured consultation process, designed to give patients clarity before any treatment begins. The team at River District Smiles walks clients through four stages: a goals discussion, digital imaging and evaluation, a review of available treatments and costs, and a personalized plan that accounts for budget, lifestyle, and comfort level. Research from the American Academy of Cosmetic Dentistry found that 99.7% of Americans believe a smile is an important social asset, while 74% feel that an unattractive smile could negatively affect a person's chances of career success. These figures reflect the significant personal and professional weight that many people place on the appearance of their teeth. Given those findings, River District Smiles' updated cosmetic range is intended to address a broad spectrum of aesthetic needs, from simple whitening to comprehensive smile makeovers using veneers or implants. The practice notes that combining multiple treatments, such as whitening alongside bonding or contouring, is an option for patients seeking a more complete transformation. "At River District Smiles, we help our Rock Hill patients improve the appearance of their teeth with treatments that look natural, feel comfortable, and last," a practice spokesperson explains. "Whether you want brighter teeth, small refinements, or a complete smile transformation, our team creates a plan that fits your goals, lifestyle, and comfort level." River District Smiles is led by Dr. Emily Hubis and Dr. Matthew Hubis, both graduates of the Medical University of South Carolina. Dr. Matthew Hubis is a current member of the Kois Center in Seattle and a fellow of the International College of Oral Implantologists, while also serving as a mentor with CEREC Doctors, enabling same-day restorations across virtually all restorative procedures. "River District Smiles is a family-owned practice that truly goes above and beyond," one patient recently noted. "The staff is incredibly kind and attentive, and they use cutting-edge treatments. What stands out most is how they make every patient feel important and cared for. You really do feel like family when you walk through their doors." Interested parties can find more information by visiting https://riverdistrictsmiles.com/
- May 21, 2026Medicine & Pharmaceuticals
How Genoscience Became a Go-To Source for Reliable Peptide Supply in the U.S.
For years, researchers across the United States have navigated a peptide supply market defined by unreliable overseas vendors, customs delays, and pricing structures that placed high-quality compounds out of reach for many institutions. Genoscience, a US-based research peptide supplier, built its business model around solving exactly that problem, and the scientific community has taken notice. The company has received a 2026 Global Recognition Award , earning top distinction in six categories: Innovation, Workplace Culture, Startup of the Year, Customer Experience, Service, and Research. The recognition places Genoscience among a select group of companies identified for advancing their industries through measurable, principled performance grounded in scientific integrity. Entering a Fragmented Market When CEO Kristelle Dammarell launched Genoscience, the domestic peptide supply landscape was dominated by unverified international suppliers and prohibitive institutional pricing that excluded research institutions at scale. Her response was deliberate: build a domestic operation capable of meeting the rigorous demands of the scientific community without sacrificing commercial viability. That operational identity took shape around Current Good Manufacturing Practice (cGMP) compliance, domestic supply chain reliability, and a transparency framework that has since become the company's defining characteristic among research institutions nationwide. Quality That Researchers Can Verify Every peptide in Genoscience's catalog undergoes High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry verification. Certificates of Analysis are made publicly available, allowing researchers to confirm purity and molecular weight before beginning any study. Independent third-party testing through Janoshik Analytical further supports the company's quality claims. The product catalog covers metabolic, CNS signaling, and cellular senescence research applications and includes compounds such as BPC-157, TB-500, Retatrutide, and Thymosin Alpha 1. This range reflects genuine scientific depth rather than a narrowly commercial catalog. Documented transparency at this level remains rare in the research chemicals market. A Domestic Supply Chain Designed for Consistency Internationally sourced research materials carry well-documented risks, including customs delays, inconsistent handling, and thermal degradation of lyophilized compounds that require careful temperature management from production through delivery. Genoscience's domestic logistics model addresses each of those vulnerabilities directly, providing researchers across the continental United States with faster and more dependable delivery. For laboratories conducting longitudinal studies, supply consistency is as operationally critical as compound purity. Genoscience introduced an industry-first subscription model that allows research facilities to automate recurring orders, securing pricing up to 60 percent below standard rates while eliminating mid-study supply disruptions that have historically compromised research timelines. Education Over Marketing Genoscience's early recognition that credibility in this sector is earned through education rather than promotion led to the development of detailed research guides, handling protocols, and compliance documentation to serve new and experienced researchers. The materials were designed to help researchers understand what they are working with, why quality standards matter, and how proper handling affects the reproducibility of results. That approach repositioned Genoscience from a transactional supplier into a knowledge resource, one that researchers return to for materials and guidance. The education-first model has strengthened long-term customer retention and broadened the company's standing within the research community, where independently verifiable processes carry more weight than promotional claims. Recognition Built on Documented Evidence Global Recognition Awards evaluates nominees through a process that begins with eligibility screening by industry experts, followed by assessment using the Rasch model. This methodology constructs a linear measurement scale across the categories of Innovation, Service, and Research. Genoscience scored highest across multiple dimensions: innovation, novelty, market impact, technological advancement, and measurable service outcomes, all corroborated by the company's documented operational record and verified manufacturing standards. The institutional research peptide market is projected to exceed $50 billion by 2026, according to global market research. Companies that combine scientific rigor with accessible supply infrastructure are well-positioned within that expanding landscape, and Genoscience's recognition reflects a sustained record of being precisely that kind of company. " Genoscience exemplifies what this award is designed to recognize: a company that has achieved genuine excellence not by cutting corners, but by doing the harder work of building trust through transparency, scientific rigor, and a real commitment to the research community it serves," said Alex Sterling, spokesperson for Global Recognition Awards. Genoscience has set a clear standard in a demanding and highly scrutinized industry that competitors will find difficult to replicate, because it is the result of deliberate operational choices made consistently at every stage of the company's development. About Global Recognition Awards Global Recognition Awards is an international organization that recognizes exceptional companies and individuals who have made significant contributions to their industries.
- May 21, 2026Medicine & Pharmaceuticals
Creative Biolabs Expands Therapeutic Model Portfolio to Accelerate Precision Drug Discovery for Chronic and Inflammatory Diseases
By integrating a suite of high-fidelity rodent models—ranging from metabolic dysfunctions to complex neurodegenerative conditions—the company aims to provide researchers with more predictive tools to bridge the gap between laboratory discovery and clinical success. Addressing Global Health Challenges through Specialized Disease Modeling As the prevalence of chronic conditions like type 2 diabetes, asthma, and autoimmune disorders continues to rise, the pharmaceutical industry faces increasing pressure to develop more effective targeted therapies. Creative Biolabs' latest expansion focuses on creating physiologically relevant environments that mimic human disease pathology with high precision. "The core challenge in modern drug development is not just finding a lead compound but ensuring its efficacy in a biological system that accurately reflects human pathophysiology," stated a senior scientist at Creative Biolabs. "Our optimized diabetic models , utilizing high-fat diets and STZ induction, allow for the rigorous testing of insulin sensitizers and glucose-lowering agents under conditions that mirror the metabolic syndrome seen in patients." Technical Insights: From Immunology to Neurology The expanded portfolio includes several key models designed to meet specific research needs: Immune-Mediated Skin Disorders: The IMQ-induced psoriasis model provides a rapid and robust platform for evaluating anti-inflammatory and immunomodulatory drugs, capturing the complex cytokine signaling pathways characteristic of human psoriasis. Respiratory Research: For pulmonary health, the OVA-induced asthma model serves as a critical benchmark for studying allergic airway inflammation and hyperresponsiveness. Neurodegenerative Advances: The company also highlights its rodent models for amyotrophic lateral sclerosis (ALS), which are essential for investigating motor neuron survival and neuroprotective strategies. Technical Analysis: Bridging the Preclinical Gap (FAQ Integration) To assist researchers in selecting the most appropriate tools, Creative Biolabs has synthesized key technical considerations into its service framework: How do these models ensure clinical relevance? By carefully selecting induction methods—such as specific dietary protocols or genetic modifications—these models replicate the histological and biochemical markers of human diseases. For instance, the gastric ulcer model is tailored to study mucosal protection and healing mechanisms. Can models be customized for specific drug mechanisms? Yes. Creative Biolabs offers flexible protocols, allowing for adjustments in dosage, timing, and strain selection to better align with the unique pharmacological profile of the client's candidate. By providing a comprehensive suite of tools—from osteoporosis induction to renal obstruction models—Creative Biolabs continues to empower the global scientific community. To explore the full range of therapeutic models and request a consultation, please visit Creative Biolabs' official website . About Creative Biolabs Creative Biolabs is a premier provider of preclinical services, specializing in the development of sophisticated animal models and therapeutic discovery platforms. With a commitment to scientific excellence and data integrity, the company supports a wide range of pharmaceutical and academic institutions worldwide.
- May 19, 2026Medicine & Pharmaceuticals
SUNX Receives 2026 Global Recognition Award For Innovation In Cellular Renewal Technology
Sunx has been awarded a 2026 Global Recognition Award in the innovation category, recognizing its work on cellular health interventions that are grounded in established molecular biology. The award particularly highlights the Sunx X1 cellular regeneration formula, which the company emphasizes as a precisely engineered intervention rather than a conventional dietary supplement relying on generalized efficacy claims. The formula is built upon SUNX's independently developed SUNX Urolithin A, which features an absorption rate 9.9 times higher than that of traditional Urolithin A, enabling more efficient improvement of the underlying cause of aging—declining mitochondrial function—thereby comprehensively optimizing the manifestations of aging. This recognition comes amid growing global attention to healthy aging. Industry analysts project that the global longevity industry will continue its steady growth through 2026, driven by aging populations and increasing pressure on healthcare systems. Many products in this space primarily focus on supplementing energy precursors (such as NAD+ pathway intermediates) but largely fail to address cellular clearance mechanisms. Sunx has structured its research agenda on the premise that progressive mitochondrial dysfunction leads to the accumulation of damaged organelles, thereby impairing cellular function and exacerbating age-related functional decline across multiple tissues. The Science Behind SUNX's Anti-Aging Technology The foundation of SUNX's anti-aging technology stems from the discovery by SUNX scientists that the underlying driver of aging is the functional decline of mitochondria — the cell's energy powerhouses. The decline in mitochondrial function leads to a cascade of issues, including reduced cellular function and stem cell damage, which in turn manifest as visible signs of aging across multiple dimensions: sleep quality, energy levels, physical stamina, reproductive health, skin condition, and more. This research has been reported in several academic journals. SUNX scientists found that Urolithin A has the potential to improve age-related mitochondrial decline. However, a serious limitation common to conventional Urolithin A and many traditional raw ingredients is poor absorption, leading to negligible efficacy upon oral intake. To overcome this, SUNX scientists applied pharmaceutical-grade processes to independently develop SUNX Urolithin A, which has an absorption rate 9.9 times higher than that of regular Urolithin A. This allows for more effective and efficient improvement of mitochondrial decline, thereby reversing cellular aging and addressing a broad spectrum of aging-related symptoms — including sleep, energy, Brain health, reproductive health, and skin condition. Multi-Target Formulation And Physiological Scope The Sunx X1 formulation is built around a multi-target matrix, in which each component is selected to engage a distinct element of the mitochondrial and cellular maintenance networks. Highly bioavailable urolithin A provides the foundation, while spermidine is included for its role in modulating mitochondrial processes, and PQQ is incorporated to support mitochondrial biogenesis and free radical handling. Botanical extracts with documented effects on glucose and lipid metabolism complete the structure, and the company states that these are intended to help stabilize the broader metabolic context in which cellular renewal takes place. Sunx reports that this architecture is designed to create a complementary loop, in which separate ingredients act on different nodes while contributing to a shared objective: preserving cellular integrity. Internal materials submitted for the award indicate that the formulation is being studied across six physiological dimensions, including sleep rhythms, Gut health, skin performance, neurological status, immune function, and the germ cell microenvironment. Preclinical investigations described in the dossier refer to reductions in aberrant inflammatory cytokine expression and increases in nerve growth factor synthesis, and user feedback collected by the company notes perceived improvements in sleep depth,cognitive clarity, skin appearance, energy levels, and elements of metabolic health. Final Words Regulatory status and quality management were notable parts of the case presented to the judging panel, as these factors define the conditions under which a consumer product can be used with confidence. The core ingredients of Sunx X1 are generally recognized as safe by United States authorities, and the finished product has been tested by SGS and the Guangzhou Customs Technical Center for compliance with physicochemical and microbiological standards widely used in international trade. The award submission also referenced more than 300 peer-reviewed articles in journals such as Nature and Cell to support the mechanisms cited. It highlighted the selection of Sunx X1 as a designated product at the 2025 Boao Enterprise Forum, indicating that the work has attracted attention in scientific and business circles. Alex Sterling of Global Recognition Awards said " Sunx Life has shown the type of innovation the programme set out to identify, because it has taken concepts from molecular biology research and shaped them into a format that can be scaled while remaining anchored in data. "Sterling also remarked that "the award reflects more than a decade of research and the technical capacity required to apply those findings at an industrial level, which was regarded as an important factor during evaluation. "The organization presented Sunx Life as an example of how sustained commitment to methodical development can yield outcomes that satisfy scientific criteria and practical requirements in a competitive market. About Global Recognition Awards Global Recognition Awards is an international organization that recognizes exceptional companies and individuals who have significantly contributed to their industry.
- May 18, 2026Medicine & Pharmaceuticals
When Families Can't Wait for Answers: How Private Autopsies Are Filling a Critical Gap in Southern Nevada
In Clark County, where the coroners office serves a large and expanding population, delays tied to heavy caseloads and limited resources can deepen grief and leave critical questions unresolved. In response to this growing need, Postmortem Pathology is providing private autopsy services in Las Vegas designed to offer families clarity, dignity, and compassion when time and answers matter most. For many families, understanding the cause of death is not simply a medical issue. It is a vital part of grieving, planning, and finding peace. Yet in a region where public resources are often stretched thin, long waiting times can add pain to an already devastating loss. Southern Nevada's unique pressures, including rapid population growth, wide service areas, and persistent strain on public infrastructure, have made access to timely postmortem answers more difficult for many residents. Postmortem Pathology was created to help fill that gap. By offering independent autopsies in Las Vegas , second opinions, and timely forensic pathology services, the organization serves families who need prompt, professional answers outside an overburdened public system. Its work is grounded in the belief that compassionate care should extend beyond death and that every family deserves the opportunity to understand what happened to their loved one without unnecessary delay. The need for a private autopsy in Las Vegas reflects a broader challenge facing communities where demand for public death investigation services continues to rise. While public medical examiner offices play an essential role, they cannot always meet every family's timeline or need for immediate closure. Private services can help bridge that divide by giving families another path forward, especially in cases where medical, legal, or personal concerns make timely answers especially important. Postmortem Pathology is committed to serving families with professionalism, sensitivity, and respect. Rather than positioning private autopsy care as a luxury, the organization views it as a necessary community resource in a region where many families cannot afford to wait for answers. Those seeking more information about available services or next steps can contact Postmortem Pathology directly to discuss how the organization may help during a difficult time. About Postmortem Pathology Postmortem Pathology provides private autopsy and forensic pathology services for families, attorneys, and healthcare professionals in Las Vegas, Nevada. The organization is dedicated to delivering timely, accurate findings with empathy and care, helping families gain clarity and closure when public systems are delayed or unable to meet urgent needs.
- May 18, 2026Medicine & Pharmaceuticals
When a Natural Death Isn’t Simple: How Sacramento Families Are Using Private Autopsies to Protect Inheritances, Resolve Insurance Claims, and Find Closure
For executors, estate attorneys, and insurance professionals, a death classified as “natural” or “undetermined” may create immediate legal and financial complications, including probate delays, disputed beneficiary claims, and life insurance denials. As these cases grow more complex, families and fiduciaries are increasingly turning to private autopsies in Sacramento performed by board-certified pathologists to establish medically sound findings that can support estate administration, insurance review, and final resolution. When the official record leaves unanswered questions, estate matters can stall. Executors may struggle to close probate if heirs challenge the circumstances of death. Attorneys may face added pressure when cause-of-death ambiguity affects the timing of distributions or raises concerns about undue influence, capacity, or policy interpretation. Insurance carriers and claims professionals may also require clearer medical evidence before approving benefits tied to accidental death riders, exclusions, or contested timelines. An Independent Autopsy Service in Sacramento can provide the detailed medical analysis needed when standard death documentation is incomplete, inconclusive, or too broad to resolve downstream disputes. Conducted independently by a board-certified forensic pathologist, the examination may include a full autopsy, review of medical records, toxicology coordination, and a written opinion regarding cause and manner of death. That evidence can help clarify key facts for probate courts, insurers, attorneys, trustees, and surviving family members. In the Private Autopsy Sacramento market, where estate values, blended families, and complex financial arrangements can intensify post-death conflicts, definitive medical findings can carry substantial practical value. A well-supported independent pathology report may help reduce speculation, strengthen claim documentation, and provide a clearer factual basis for legal and financial decision-making. It can also help families avoid prolonged disputes that increase administrative costs and deepen emotional strain. Private autopsies are not a replacement for legal counsel or insurer review. However, when unresolved medical questions threaten inheritances, delay claim payments, or leave survivors without answers, an independent forensic examination can become a critical step toward both evidentiary clarity and personal closure. About Postmortem Pathology Postmortem Pathology is a Sacramento-based forensic pathology practice providing independent autopsies, medical record reviews, and cause-of-death evaluations for families, attorneys, fiduciaries, and insurance stakeholders. Led by board-certified pathologists, the firm delivers objective medical findings to support informed legal, financial, and personal decisions following complex or disputed deaths.
ALL NEWS
- Polytechnitis Handyman Services Launched for Canberra and Border NSW Homes
- Estelion Medical Expands Bulgaria-Focused Dental Tourism Services as European Demand Continues to Grow
- Only 3 of 67 Popular AI Tools Are Fully Free, and Paid-Only Options Are Growing, New Directory's Review Finds
- Konstantin Vision & Eyewear Center introduces same day glasses NYC support in Manhattan
- Honoring a Living Legend - The Estate of Carol & Bruno Sammartino - Real Estate & Estate Contents Auction
- UK Car Key Assist Expands 24-Hour Auto Locksmith Matching Service
- Key Crafters Limited Highlights Need for Specialist Car Key Programming Equipment
- Newsgates.com Expands as a Modern Digital News Platform Open to Global Partnerships
- GenOptima Maps the Chinese AI Model Ecosystem for Brand Visibility in 2026
- Wali Qasemi Reveals Top Proven Methods That Boosts Your Email Marketing Sales Quickly
- PatientGain.com Launches Healthcare Marketing AI Agents Using Human-In-The-Loop Technology
- GenOptima Leads 2026 Ranking of AI Search Optimization Agencies Focused on Citation Outcomes
- CloseCircle.io Announces Compliance Infrastructure Expansion for Digital Creators Amid New EU CESOP and VAT Reporting Framework Changes
- Nadezhda Grishaeva Announces Cannes 2026 Appearance Highlighting Hybrid Lifestyle Culture
- Taklimakan Rally 2026: GWM Through the Inferno, Talk of Champions
- Identity Unbound: How MyyShop is Architecting the Era of "Lightweight Commerce" for the New Generation Social Entrepreneur
- HackerNoon, Nosana, Arweave and MEXC Launch Decentralize AI Hackathon With Over $50,000 in Rewards
- Applite Solutions LLC Exhibited AI-Powered Revenue Cycle Management At Health 2.0 Conference, 2026 Edition
COMMUNICATE. COMMAND. COMMERCE.
Lead the conversation of your brand & win more customers with MarketersMEDIA Solutions.
Explore Now
Google
RSS